CN113348368A - 基于生物标志物开具远程患者管理处方 - Google Patents

基于生物标志物开具远程患者管理处方 Download PDF

Info

Publication number
CN113348368A
CN113348368A CN202080010888.0A CN202080010888A CN113348368A CN 113348368 A CN113348368 A CN 113348368A CN 202080010888 A CN202080010888 A CN 202080010888A CN 113348368 A CN113348368 A CN 113348368A
Authority
CN
China
Prior art keywords
level
fragments
biomarker
patient
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080010888.0A
Other languages
English (en)
Chinese (zh)
Inventor
T·斯图贝
J·维默尔
J·坤德
S·贾里格
F·克勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAHMS GmbH
Original Assignee
BRAHMS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP19166382.2A external-priority patent/EP3715851A1/en
Application filed by BRAHMS GmbH filed Critical BRAHMS GmbH
Publication of CN113348368A publication Critical patent/CN113348368A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
CN202080010888.0A 2019-03-29 2020-03-27 基于生物标志物开具远程患者管理处方 Pending CN113348368A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19166425.9 2019-03-29
EP19166382.2A EP3715851A1 (en) 2019-03-29 2019-03-29 Prescription of remote patient management based on biomarkers
EP19166382.2 2019-03-29
EP19166425 2019-03-29
EP19175720.2 2019-05-21
EP19175720 2019-05-21
PCT/EP2020/058700 WO2020201078A1 (en) 2019-03-29 2020-03-27 Prescription of remote patient management based on biomarkers

Publications (1)

Publication Number Publication Date
CN113348368A true CN113348368A (zh) 2021-09-03

Family

ID=69941398

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080010888.0A Pending CN113348368A (zh) 2019-03-29 2020-03-27 基于生物标志物开具远程患者管理处方

Country Status (8)

Country Link
US (2) US12442825B2 (https=)
EP (1) EP3948301A1 (https=)
JP (2) JP7575400B2 (https=)
CN (1) CN113348368A (https=)
AU (1) AU2020253042B2 (https=)
BR (1) BR112021019479A2 (https=)
CA (3) CA3281050A1 (https=)
WO (1) WO2020201078A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11783944B2 (en) * 2019-09-09 2023-10-10 Neal F. Krouse System for live monitoring of vitals for patients and physicians
WO2022101937A1 (en) * 2020-11-12 2022-05-19 Shah Komal An integrated health data capture and analysis based device for evaluation, diagnosis and prognosis of heart failure
WO2022164724A1 (en) * 2021-01-27 2022-08-04 Verantos, Inc. High validity real-world evidence study with deep phenotyping
WO2022245405A1 (en) 2021-05-17 2022-11-24 Verantos, Inc. System and method for term disambiguation
US20240120105A1 (en) * 2022-10-09 2024-04-11 Morteza Naghavi Predicting adverse health risk based on ct scan images and ai-enabled cardiovascular structure volumetry
WO2025097159A1 (en) * 2023-11-05 2025-05-08 3Ive Labs, Llc Urinary oxygen and uses thereof in adaptive therapies for kidney function

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2107377A1 (en) * 2008-04-04 2009-10-07 BRAHMS Aktiengesellschaft Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events
CN103080746A (zh) * 2010-08-26 2013-05-01 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
CN108931658A (zh) * 2018-04-16 2018-12-04 上海交通大学医学院附属瑞金医院 用于诊断心力衰竭合并症及预后评估的血清标记物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943918A (en) 1971-12-02 1976-03-16 Tel-Pac, Inc. Disposable physiological telemetric device
US4121573A (en) 1973-10-04 1978-10-24 Goebel Fixture Co. Wireless cardiac monitoring system and electrode-transmitter therefor
FR2570703B1 (fr) 1984-09-26 1988-07-08 Commissariat Energie Atomique Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
US4827943A (en) 1986-09-23 1989-05-09 Advanced Medical Technologies, Inc. Portable, multi-channel, physiological data monitoring system
US4784162A (en) 1986-09-23 1988-11-15 Advanced Medical Technologies Portable, multi-channel, physiological data monitoring system
US4882733A (en) 1987-03-13 1989-11-21 Ford Aerospace Corporation Method and apparatus for combining encoding and modulation
US5511553A (en) 1989-02-15 1996-04-30 Segalowitz; Jacob Device-system and method for monitoring multiple physiological parameters (MMPP) continuously and simultaneously
US5307818A (en) 1989-02-15 1994-05-03 Jacob Segalowitz Wireless electrocardiographic and monitoring system and wireless electrode assemblies for same
US4981141A (en) 1989-02-15 1991-01-01 Jacob Segalowitz Wireless electrocardiographic monitoring system
US5168874A (en) 1989-02-15 1992-12-08 Jacob Segalowitz Wireless electrode structure for use in patient monitoring system
FR2664699B1 (fr) 1990-07-13 1995-08-18 Cis Bio Int Procede d'amplification du signal d'emission d'un compose luminescent.
US5353793A (en) 1991-11-25 1994-10-11 Oishi-Kogyo Company Sensor apparatus
US5214939A (en) 1991-11-25 1993-06-01 Carrier Corporation Variable area refrigerant expansion device having a flexible orifice
ES2155068T3 (es) 1992-04-03 2001-05-01 Micromedical Ind Ltd Sistema de supervision fisiologica.
US5522396A (en) 1992-05-12 1996-06-04 Cardiac Telecom Corporation Method and system for monitoring the heart of a patient
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US5544661A (en) 1994-01-13 1996-08-13 Charles L. Davis Real time ambulatory patient monitor
DE19847690A1 (de) 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
US6416471B1 (en) 1999-04-15 2002-07-09 Nexan Limited Portable remote patient telemonitoring system
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
DE102006060112A1 (de) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
DE102007022367A1 (de) 2007-05-07 2008-11-20 B.R.A.H.M.S Ag Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2107377A1 (en) * 2008-04-04 2009-10-07 BRAHMS Aktiengesellschaft Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events
CN103080746A (zh) * 2010-08-26 2013-05-01 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
CN108931658A (zh) * 2018-04-16 2018-12-04 上海交通大学医学院附属瑞金医院 用于诊断心力衰竭合并症及预后评估的血清标记物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FRIEDRICH KOEHLER .ET AL: "Telemedicine in heart failure: Pre-specified and exploratory subgroup analyses from the TIM-HF trial", 《INTERNATIONAL JOURNAL OF CARDIOLOGY》, vol. 161, no. 3, 29 September 2012 (2012-09-29), pages 143 - 150, XP028959239, DOI: 10.1016/j.ijcard.2011.09.007 *
J. AMER: "Primary Results of the HABIT Trial (Heart Failure Assessment With BNP in the Home)", 《 COLLEGE OF CARDIOL》, vol. 61, no. 16, 1 April 2013 (2013-04-01), pages 1726 - 1735, XP055172714, DOI: 10.1016/j.jacc.2013.01.052 *
KOEHLER FRIEDRICH ET AL: "Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial", 《LANCET》, vol. 392, no. 101, 25 August 2018 (2018-08-25), pages 1047 - 1057, XP085481460, DOI: 10.1016/S0140-6736(18)31880-4 *
RUI XIANG: "Meta-analysis and meta-regression of telehealth programmes for patients with chronic heart failure", 《JOURNAL OF TELEMEDICINE AND TELECARE》, vol. 19, no. 5, 9 July 2013 (2013-07-09), pages 249, XP009514627, DOI: 10.1177/1357633X13495490 *
崔洁;周京敏;: "心力衰竭生物标志物的研究", 中华心脏与心律电子杂志, no. 02, 25 May 2015 (2015-05-25), pages 4 - 6 *

Also Published As

Publication number Publication date
CA3281050A1 (en) 2026-03-02
US20220260589A1 (en) 2022-08-18
CA3281038A1 (en) 2026-03-02
JP7575400B2 (ja) 2024-10-29
AU2020253042A1 (en) 2021-06-17
BR112021019479A2 (pt) 2021-11-30
CA3124744A1 (en) 2020-10-08
AU2020253042B2 (en) 2025-10-02
US20250369987A1 (en) 2025-12-04
JP2025015545A (ja) 2025-01-30
WO2020201078A1 (en) 2020-10-08
US12442825B2 (en) 2025-10-14
JP2022526507A (ja) 2022-05-25
EP3948301A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
US20250369987A1 (en) Prescription of remote patient management based on biomarkers
Joseph et al. A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry
Cataliotti et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling
JP6788050B2 (ja) 主要有害心イベントのリスクを予測する方法
Gunsolus et al. Renal dysfunction influences the diagnostic and prognostic performance of high-sensitivity cardiac troponin I
Frank Peacock et al. Short‐term mortality risk in emergency department acute heart failure
Authors/Task Force Members et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)
Keller et al. Copeptin improves early diagnosis of acute myocardial infarction
Patton et al. N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study
Potocki et al. Comparison of midregional pro‐atrial natriuretic peptide with N‐terminal pro‐B‐type natriuretic peptide in the diagnosis of heart failure
Rosenberg et al. Osteopontin predicts adverse right ventricular remodelling and dysfunction in pulmonary hypertension
Bettencourt Clinical usefulness of B-type natriuretic peptide measurement: present and future perspectives
Mejhert et al. Predicting readmissions and cardiovascular events in heart failure patients
Collinson et al. The clinical and diagnostic performance characteristics of the high sensitivity Abbott cardiac troponin I assay
van Peet et al. Plasma NT-proBNP as predictor of change in functional status, cardiovascular morbidity and mortality in the oldest old: the Leiden 85-plus study
Boyer et al. Biomarker changes during acute heart failure treatment
Gaheen et al. Plasma copeptin levels in children with pulmonary arterial hypertension associated with congenital heart disease
Gruson et al. The multidimensional value of natriuretic peptides in heart failure, integrating laboratory and clinical aspects
Vallée Association between serum uric acid and arterial stiffness in a large‐aged 40–70 years old population
de la Espriella et al. Early urinary sodium trajectory and risk of adverse outcomes in acute heart failure and renal dysfunction
Meune et al. Utility of 14 novel biomarkers in patients with acute chest pain and undetectable levels of conventional cardiac troponin
Whalley et al. Prognostic role of echocardiography and brain natriuretic peptide in symptomatic breathless patients in the community
Nielsen et al. Neuroendocrine testing in community patients with heart disease: plasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability
Golcuk et al. Predictive cutoff point of admission N-terminal pro–B-type natriuretic peptide testing in the ED for prognosis of patients with acute heart failure
EP3715851A1 (en) Prescription of remote patient management based on biomarkers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination